<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Anemia and the kidney transplant recipient
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Anemia and the kidney transplant recipient
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Anemia and the kidney transplant recipient
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Daniel W Coyne, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Daniel C Brennan, MD, FACP
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Andrew Malone, MB, BCh, FASN, FRCPI
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Christophe Legendre, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John Vella, MD, FACP, FRCP, FASN, FAST
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Albert Q Lam, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Mar 03, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H2871634793">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Anemia, usually defined as hemoglobin (Hb) &lt;12 g/dL in females and &lt;13 g/dL in males, is a common finding before and after kidney transplantation. It is most often related to iron deficiency, graft rejection or dysfunction, erythropoietin (EPO) deficiency, viral infection, immunosuppression, and infection prophylaxis medications.
        </p>
        <p>
         This topic will review the epidemiology, pathogenesis, evaluation, and treatment of anemia in kidney transplant recipients. Anemia associated with chronic kidney disease (CKD) in the nontransplant setting and the benefits of the treatment of anemia in the setting of CKD are discussed elsewhere. Both topic reviews are relevant since most transplant recipients have an average estimated glomerular filtration rate (eGFR) &lt;60 mL/min/1.73 m
         <sup>
          2
         </sup>
         , a level consistent with the existing definition of CKD.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1926.html" rel="external">
          "Treatment of anemia in patients on dialysis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1952.html" rel="external">
          "Treatment of anemia in nondialysis chronic kidney disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3150391308">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The prevalence of anemia after kidney transplantation varies depending upon the definition of anemia used, the time period posttransplant, immunosuppressive regimen, and frequency of treatment [
         <a href="#rid1">
          1-12
         </a>
         ]. While anemia is present in almost 90 percent of patients within the first month posttransplant, the prevalence falls to 34 to 45 percent among patients more than one year posttransplant [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
         At the time of transplantation, most adult patients can be defined as anemic as target levels for hemoglobin (Hb) among United States patients on dialysis are generally 10 to 11 g/dL. Mean Hb levels rise to above 11 g/dL by three months posttransplant and to above 12 g/dL at 6 to 12 months posttransplant. Development of acute or chronic allograft dysfunction is almost invariably accompanied by worsening anemia. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         At six months posttransplant, approximately one-half of patients have an Hb level that is below normal (defined here as &lt;14 g/dL in males and &lt;12 g/dL in females) [
         <a href="#rid2">
          2,7,12
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         At one year, 10 to 40 percent are anemic despite having normal graft function [
         <a href="#rid2">
          2,7,12-14
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         During the first five-year posttransplant period, approximately one-third of patients have Hb levels that are &lt;12 g/dL [
         <a href="#rid3">
          3,4
         </a>
         ]. More severe anemia, characterized by an Hb level &lt;11 g/dL, occurs in 12 to 15 percent of patients [
         <a href="#rid7">
          7,15
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a registry study from 20 European countries of 3699 pediatric (&lt;18 years old) patients transplanted between 2000 and 2012, 49.8 percent were anemic, according to the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF KDOQI) classification, which defines anemia in children as Hb below the 5
         <sup>
          th
         </sup>
         percentile for age and sex [
         <a href="#rid16">
          16
         </a>
         ]. By contrast, the United Kingdom National Institute for Health and Care Excellence (NICE) guidelines for anemia in CKD suggest a target Hb of 9.5 to 11.5 g/dL in patients &lt;2 years old, and 10 to 12 g/dL for all others. Using these criteria, just 7.8 percent of pediatric kidney transplants were anemic.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H398802061">
         <span class="h1">
          PATHOGENESIS AND RISK FACTORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The pathogenesis of anemia posttransplant varies by time from transplant. General risk factors associated with the development of anemia in the kidney transplant patient include female sex, age, allograft dysfunction, use of angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), and choice of immunosuppressive agents [
         <a href="#rid2">
          2-4,6,17,18
         </a>
         ]. Use of erythropoiesis-stimulating agent (ESA) or iron therapy can paradoxically associate with anemia due to treatment by indication bias.
        </p>
        <p class="headingAnchor" id="H630064213">
         <span class="h2">
          Early posttransplantation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Anemia immediately posttransplant is almost universally due to lower-than-normal hemoglobin (Hb) targets in the chronic kidney disease (CKD) and end-stage kidney disease (ESKD) populations, surgical blood loss, and frequent phlebotomy. Dilutional anemia also occurs because of aggressive perioperative volume expansion. Recovery to normal adult Hb concentrations can be hindered by allograft dysfunction and other clinical events, increased donor age, and iron deficiency.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Inadequate erythropoietin (EPO)
         </strong>
         – Improvement of erythropoiesis after kidney transplantation is due to EPO production in the allograft and the loss of the uremic milieu. In general, EPO levels begin to rise on posttransplant day 2 and reach a fourfold elevation for two to three weeks, after which time restoration of negative feedback control occurs [
         <a href="#rid19">
          19,20
         </a>
         ]. Early EPO surges may be inefficient in correcting anemia since the hormone seems to be inefficient in this persistent uremic setting [
         <a href="#rid21">
          21,22
         </a>
         ]. Relative EPO deficiency in the setting of allograft dysfunction is likely similar to that observed with anemia in patients with nontransplant-associated CKD.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         However, endocrine function of the graft may not always correlate with excretory function, perhaps because peritubular interstitial cells, which produce EPO, are selectively damaged or develop defective regulation. Anemia may also correct in some patients despite relatively low EPO levels [
         <a href="#rid15">
          15,23
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Iron deficiency
         </strong>
         – Iron deficiency plays a major role in persistent anemia in the immediate posttransplant period. Despite the recognition of iron requirements for effective ESA therapy, iron deficiency remains common among patients presenting for kidney transplantation. Iron stores may be rapidly depleted posttransplant due to surgical blood loss, frequent phlebotomy, and utilization of stores for enhanced erythropoiesis [
         <a href="#rid8">
          8
         </a>
         ]. Return of regular menses resulting in iron losses may further contribute to iron deficiency in females. Chronic use of proton pump inhibitors (PPIs) in kidney transplant recipients is also associated with iron deficiency [
         <a href="#rid24">
          24
         </a>
         ]. This may be due to PPIs impairing iron absorption by enterocytes.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Regulation of iron absorption and mobilization from iron stores to support erythropoiesis is impaired in the initial posttransplant period and during most acute rejection episodes. Serum hepcidin is the regulator of intestinal iron absorption and release of iron from reticuloendothelial stores. Hepcidin is cleared by the kidney, and therefore its levels increase as kidney function declines. Consequently, hepcidin levels are elevated in most patients on dialysis, leading to poor iron absorption and mobilization for erythropoiesis. Elevated hepcidin levels are seen in many kidney transplant patients and correlate with poor transplant function, higher ferritin, and other inflammatory markers [
         <a href="#rid25">
          25,26
         </a>
         ]. Interleukin (IL)-6, a major regulator of hepcidin production, has been shown to be elevated immediately posttransplant and in the setting of acute rejection [
         <a href="#rid27">
          27,28
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The accurate assessment of iron stores posttransplant is difficult because ferritin is a positive acute-phase reactant while transferrin saturation (TSAT) varies inversely with acute-phase reactants. A high ferritin may reflect adequate iron stores, inflammation, or both, while low TSAT may be due to low iron stores, inflammation, or both. This combination of high ferritin and low TSAT is characteristic of the anemia of chronic disease and reflects the actions of IL-6, hepcidin, and other inflammatory signals mentioned above. Acute or chronic rejection, progressive decline in kidney function, and inflammation or infection may lead to elevated ferritin. Conversely, ferritin levels fall with iron utilization but also rise with increased gastrointestinal iron absorption following transplantation. Thus, ferritin measurements have inconsistently reflected iron stores among kidney transplant recipients and do not always correlate with anemia [
         <a href="#rid7">
          7,15
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7150.html" rel="external">
          "Causes and diagnosis of iron deficiency and iron deficiency anemia in adults", section on 'Iron studies (list of available tests)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Donor kidney characteristics
         </strong>
         – Cold and warm ischemia times do not correlate with EPO levels [
         <a href="#rid29">
          29,30
         </a>
         ]. Patients with delayed graft function have a slower rise in EPO levels, which increase with improvement in graft function. Interstitial fibrosis and tubular atrophy in the donor kidney at the time of transplant associate independently with anemia at 12 months posttransplant [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3907012192">
         <span class="h2">
          Later (&gt;3 months) posttransplantation
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Immunosuppressive agents
         </strong>
         – The antimetabolites
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         mofetil (MMF), enteric-coated mycophenolate sodium (EC-MPS), and
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         cause marrow suppression and can also result in anemia [
         <a href="#rid2">
          2,17,32
         </a>
         ]. However, the mean relative decrease in Hb concentration with these drugs may only be 0.2 to 0.3 g/dL, respectively [
         <a href="#rid2">
          2
         </a>
         ]. More severe anemia is sometimes seen with these agents and responds to a reduction in dose.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">
          Sirolimus
         </a>
         also causes marrow suppression and anemia, particularly early after initiation, but the effect may lessen over time [
         <a href="#rid33">
          33-37
         </a>
         ]. In general, the calcineurin inhibitors do not cause marrow suppression directly and do not typically cause anemia. However, sirolimus and the calcineurin inhibitors (
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         and
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         ) may cause thrombotic microangiopathy and hemolytic anemia [
         <a href="#rid23">
          23,38
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7329.html" rel="external">
          "Pharmacology of mammalian (mechanistic) target of rapamycin (mTOR) inhibitors", section on 'Hematologic effects'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other medications
         </strong>
         – The use of ACE inhibitors and ARBs has correlated with anemia in a dose-related fashion in kidney transplant patients [
         <a href="#rid17">
          17,18
         </a>
         ]. Based upon these effects, these medications may be used to treat posttransplant erythrocytosis [
         <a href="#rid2">
          2,38
         </a>
         ]. Other medications commonly used in kidney transplant patients that may cause anemia include
         <a class="drug drug_general" data-topicid="8485" href="/z/d/drug information/8485.html" rel="external">
          ganciclovir
         </a>
         ,
         <a class="drug drug_general" data-topicid="10058" href="/z/d/drug information/10058.html" rel="external">
          valganciclovir
         </a>
         , and
         <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">
          trimethoprim-sulfamethoxazole
         </a>
         (TMP-SMX). Use of
         <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">
          dapsone
         </a>
         for
         <em>
          Pneumocystis jirovecii
         </em>
         pneumonia prophylaxis has been associated with a higher risk of anemia than
         <a class="drug drug_general" data-topicid="8957" href="/z/d/drug information/8957.html" rel="external">
          atovaquone
         </a>
         [
         <a href="#rid39">
          39
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7348.html" rel="external">
          "Kidney transplantation in adults: Posttransplant erythrocytosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Graft dysfunction and rejection
         </strong>
         – In kidney transplant recipients, serum creatinine levels that are &gt;2 mg/dL (177 micromol/L) correlate strongly with anemia [
         <a href="#rid32">
          32
         </a>
         ]. In addition, episodes of acute rejection also have correlated with an average decrease of 0.5 g/dL in the Hb concentration, which may be due to decreased EPO levels [
         <a href="#rid20">
          20,30
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients returning to hemodialysis following failure of their kidney transplant suffer from a chronic inflammatory state that is associated with resistance to ESAs [
         <a href="#rid40">
          40
         </a>
         ]. A transplant nephrectomy in symptomatic patients ameliorates markers of chronic inflammation and leads to recovery of sensitivity to ESAs.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Donor and recipient characteristics
         </strong>
         – Donor age &gt;50 to 60 years has been associated with a decrease in EPO levels and an increased incidence of anemia [
         <a href="#rid2">
          2,30,32
         </a>
         ]. Female recipients are more likely to have posttransplant Hb levels &lt;12 g/dL at 6 and 12 months. This may be due to increased iron loss with menses and androgen deficiency relative to males [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Infections
         </strong>
         – Infections, including those due to parvovirus B19, Epstein-Barr virus (EBV), cytomegalovirus (CMV), BK polyomavirus, varicella-zoster virus, tuberculosis, herpesviruses, and staphylococci, have also been associated with an increased risk of anemia [
         <a href="#rid23">
          23,41
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8272.html" rel="external">
          "Clinical manifestations and diagnosis of parvovirus B19 infection", section on 'Transient aplastic crisis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8283.html" rel="external">
          "Clinical manifestations and treatment of Epstein-Barr virus infection", section on 'Other manifestations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other causes
         </strong>
         – Other causes of anemia in the later posttransplantation setting include certain comorbid conditions (new diagnoses of heart failure, gastritis, peripheral vascular disease, and cerebrovascular accident) [
         <a href="#rid2">
          2
         </a>
         ], secondary hyperparathyroidism [
         <a href="#rid1">
          1-6
         </a>
         ], and folate and vitamin B12 deficiency [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The passenger leukocyte syndrome is a very rare cause of hemolytic anemia in solid organ transplant recipients that occurs in the setting of ABO-compatible or Rh-compatible, but nonidentical, donor and recipient mismatches [
         <a href="#rid43">
          43-48
         </a>
         ]. Passenger leukocyte syndrome most commonly occurs following transplantation of an organ from a donor with ABO-O blood type into a recipient with ABO-A or -B blood type or from an Rh-negative donor into an Rh-positive recipient. The donor organ contains B cells and plasma cells (so-called passenger leukocytes) that produce anti-isoagglutinin or anti-Rh antibodies that lead to the syndrome. Passenger leukocyte syndrome typically presents as a mild hemolytic anemia with an acute onset within the first few weeks posttransplantation. The diagnosis is made by the direct antiglobulin (Coombs) test. Treatment is usually supportive, although plasmapheresis and cytolytic therapy have been used. The clinical course is typically self-limiting, although antibodies may persist at detectable levels for 12 to 851 days posttransplantation [
         <a href="#rid49">
          49
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7078.html" rel="external">
          "Warm autoimmune hemolytic anemia (AIHA) in adults", section on 'Associated conditions'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1357614719">
         <span class="h1">
          SURVEILLANCE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Kidney transplant recipients should undergo regular surveillance for anemia after transplantation with a complete blood count (CBC). At most transplant centers, a CBC is obtained at least weekly for the first three months and then every two to four weeks for a year and then monthly to every three months thereafter. (See
         <a class="medical medical_review" href="/z/d/html/14039.html" rel="external">
          "Overview of care of the adult kidney transplant recipient", section on 'Routine follow-up and laboratory monitoring'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         Most transplant recipients are anemic at the time of transplant and during the early posttransplant period, but hemoglobin (Hb) levels are expected to gradually increase over the first three months posttransplant if the allograft is functioning (see
         <a class="local">
          'Epidemiology'
         </a>
         above). Thus, our approach to patients who are found to be anemic on routine screening is as follows:
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         All patients should have an assessment of iron stores (serum iron, total iron-binding capacity, percent transferrin saturation [TSAT], serum ferritin).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients who are less than three months posttransplant, we generally do
         <strong>
          not
         </strong>
         perform a further diagnostic evaluation for anemia unless the Hb level decreases to below the level at the time of transplant.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients whose Hb levels fail to normalize after three months posttransplant, we perform a diagnostic evaluation for anemia. (See
         <a class="local">
          'Diagnostic evaluation'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients whose Hb levels normalize by three months posttransplant, we continue to monitor for recurrent anemia and perform a diagnostic evaluation if anemia is observed. (See
         <a class="local">
          'Diagnostic evaluation'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1950820922">
         <span class="h1">
          DIAGNOSTIC EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Kidney transplant recipients are evaluated for anemia and iron deficiency at the time of transplantation. In addition, kidney transplant recipients with persistent anemia at three months posttransplant or new-onset anemia after three months posttransplant (see
         <a class="local">
          'Surveillance'
         </a>
         above) should undergo further diagnostic evaluation. This evaluation should include an assessment for causes of anemia shared with nontransplant patients, as well as for more specific causes that may be unique to kidney transplant recipients (see
         <a class="medical medical_review" href="/z/d/html/7133.html" rel="external">
          "Diagnostic approach to anemia in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7076.html" rel="external">
          "Diagnosis of hemolytic anemia in adults"
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Assessment for history of blood loss
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Assessment for symptoms and/or signs of infection (eg, fever, malaise)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Assessment of dietary intake
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Assessment of medication history for potentially causative medications (eg,
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         mofetil [MMF], enteric-coated mycophenolate sodium [EC-MPS],
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         , mammalian [mechanistic] target of rapamycin [mTOR] inhibitors, angiotensin-converting enzyme [ACE] inhibitors, angiotensin receptor blockers [ARBs],
         <a class="drug drug_general" data-topicid="8485" href="/z/d/drug information/8485.html" rel="external">
          ganciclovir
         </a>
         ,
         <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">
          trimethoprim-sulfamethoxazole
         </a>
         [TMP-SMX])
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Assessment of kidney allograft function (serum creatinine, spot urine protein-to-creatinine ratio)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Red blood cell (RBC) indices
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reticulocyte count
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Iron studies (serum iron, total iron-binding capacity, percent transferrin saturation [TSAT], serum ferritin)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Testing for presence of hemolysis (eg, indirect bilirubin, lactate dehydrogenase, haptoglobin)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Testing for folate and vitamin B12 deficiency
        </p>
        <p>
        </p>
        <p>
         We do not routinely evaluate all anemic transplant recipients for infection with parvovirus B19 or other viruses. However, if the initial diagnostic evaluation as detailed above does not identify a clear cause of anemia, we perform testing for parvovirus B19 infection by means of nucleic acid amplification testing (NAAT). (See
         <a class="medical medical_review" href="/z/d/html/8272.html" rel="external">
          "Clinical manifestations and diagnosis of parvovirus B19 infection", section on 'Nucleic acid detection'
         </a>
         .)
        </p>
        <p>
         An accurate assessment of iron stores in kidney transplant recipients can be challenging. While low levels of ferritin and TSAT indicate true deficiency, inflammation may suppress TSAT and increase ferritin, obscuring the diagnostic utility of these tests. In addition, since no prospective studies have defined specific ferritin and TSAT levels for transplant recipients, criteria from the 2012 Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Anemia in Chronic Kidney Disease are used to define iron deficiency [
         <a href="#rid50">
          50
         </a>
         ]. (See
         <a class="local">
          'Early posttransplantation'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/1939.html" rel="external">
          "Inflammation in patients with kidney function impairment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1951.html" rel="external">
          "Diagnosis of iron deficiency in chronic kidney disease"
         </a>
         .)
        </p>
        <p>
         The concurrent presence of leukopenia, thrombocytopenia, and/or acute kidney allograft dysfunction suggests the following potential causes of anemia:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Global myelosuppression is commonly caused by immunosuppression, nutritional deficiency, and prophylactic medications but can also be seen in the setting of viral infections. (See
         <a class="local">
          'Later (&gt;3 months) posttransplantation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hemolytic uremic syndrome should be suspected when anemia is associated with kidney dysfunction, thrombocytopenia, and evidence of microangiopathic hemolytic anemia. (See
         <a class="medical medical_review" href="/z/d/html/1331.html" rel="external">
          "Pathophysiology of TTP and other primary thrombotic microangiopathies (TMAs)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7350.html" rel="external">
          "Thrombotic microangiopathy after kidney transplantation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         By comparison, the presence of anemia alone, without leukopenia or thrombocytopenia, along with a low reticulocyte count and no nutritional deficiencies suggest parvovirus B19 infection or, very rarely, anti-erythropoietin (EPO) antibodies [
         <a href="#rid51">
          51
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8272.html" rel="external">
          "Clinical manifestations and diagnosis of parvovirus B19 infection"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1930.html" rel="external">
          "Pure red cell aplasia (PRCA) due to anti-erythropoiesis-stimulating agent antibodies"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1074475226">
         <span class="h1">
          TREATMENT
         </span>
        </p>
        <p class="headingAnchor" id="H142006455">
         <span class="h2">
          General principles
         </span>
         <span class="headingEndMark">
          —
         </span>
         The general principles of anemia management in patients with chronic kidney disease (CKD) or end-stage kidney disease (ESKD) also apply to the treatment of anemia in kidney transplant recipients. These include treatment of the underlying cause of anemia (if identified), treatment of iron deficiency (if present), and the use of erythropoiesis-stimulating agents (ESAs) to reduce the need for red blood cell (RBC) transfusions. The selection of individual therapy depends upon the severity of anemia and the presence of iron deficiency. As treatment of iron deficiency may resolve the anemia, it should be treated before the administration of ESAs.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1952.html" rel="external">
          "Treatment of anemia in nondialysis chronic kidney disease"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1926.html" rel="external">
          "Treatment of anemia in patients on dialysis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1943.html" rel="external">
          "Treatment of iron deficiency in patients with nondialysis chronic kidney disease (CKD)"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1953.html" rel="external">
          "Treatment of iron deficiency in patients on dialysis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Special considerations in the treatment of anemia in kidney transplant recipients include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Target hemoglobin levels
         </strong>
         – The optimal target hemoglobin (Hb) level for kidney transplant recipients is not well defined and may differ depending upon kidney allograft function and patient functional status.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management of immunosuppression and other medications
         </strong>
         – Immunosuppressive agents (
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         mofetil [MMF], enteric-coated mycophenolate sodium [EC-MPS],
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         ,
         <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">
          sirolimus
         </a>
         ) and other medications (eg, angiotensin-converting enzyme [ACE] inhibitors, angiotensin receptor blockers [ARBs],
         <a class="drug drug_general" data-topicid="8485" href="/z/d/drug information/8485.html" rel="external">
          ganciclovir
         </a>
         ,
         <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">
          trimethoprim-sulfamethoxazole
         </a>
         [TMP-SMX]) are common causes of posttransplant anemia. Dose reduction or discontinuation of these agents may be indicated depending upon the time from transplant and status of the kidney allograft. (See
         <a class="local">
          'Later (&gt;3 months) posttransplantation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Use of iron
         </strong>
         – Both oral and intravenous (IV) iron have been found to be safe and effective in kidney transplant recipients [
         <a href="#rid52">
          52
         </a>
         ]. Due to the already high pill burden of transplant patients, we prefer IV iron therapy over oral iron therapy whenever known or suspected iron deficiency anemia is present [
         <a href="#rid53">
          53
         </a>
         ]. Several IV iron formulations are available, including
         <a class="drug drug_general" data-topicid="8936" href="/z/d/drug information/8936.html" rel="external">
          ferric gluconate
         </a>
         ,
         <a class="drug drug_general" data-topicid="9004" href="/z/d/drug information/9004.html" rel="external">
          iron sucrose
         </a>
         ,
         <a class="drug drug_general" data-topicid="9044" href="/z/d/drug information/9044.html" rel="external">
          ferumoxytol
         </a>
         ,
         <a class="drug drug_general" data-topicid="90237" href="/z/d/drug information/90237.html" rel="external">
          ferric carboxymaltose
         </a>
         ,
         <a class="drug drug_general" data-topicid="120585" href="/z/d/drug information/120585.html" rel="external">
          ferric derisomaltose
         </a>
         , and
         <a class="drug drug_general" data-topicid="8574" href="/z/d/drug information/8574.html" rel="external">
          iron dextran
         </a>
         . All of these products are comparably effective in treating iron deficiency. The selection of an IV iron formulation may vary by institutional preference. (See
         <a class="medical medical_review" href="/z/d/html/7148.html" rel="external">
          "Treatment of iron deficiency anemia in adults", section on 'Choice of IV formulation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1943.html" rel="external">
          "Treatment of iron deficiency in patients with nondialysis chronic kidney disease (CKD)", section on 'Intravenous iron'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In our experience, oral iron has been inadequate to replace or maintain adequate iron stores and may bind with immunosuppressant medications, such as MMF/MPS. The phosphate binder
         <a class="drug drug_general" data-topicid="96959" href="/z/d/drug information/96959.html" rel="external">
          ferric citrate
         </a>
         is approved for the treatment of iron deficiency anemia in CKD but has not been studied in the kidney transplant population. Like other oral iron preparations, this agent may bind to immunosuppressants.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Posttransplant erythrocytosis may develop in patients receiving oral iron supplementation. Hb often decreases four weeks after iron discontinuation in this setting [
         <a href="#rid4">
          4,12
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Use of ESAs
         </strong>
         – The use of ESAs in kidney transplant recipients varies depending upon the time from transplantation. As an example, we do not use ESAs in the immediate transplant period. With anemia of CKD occurring more than three months posttransplant in the iron-replete patient, we may initiate an ESA. Patients receiving an ESA should be apprised of the risks of stroke, thrombotic events, and possibly increased risk of recurrent cancer prior to ESA use. (See
         <a class="medical medical_review" href="/z/d/html/1952.html" rel="external">
          "Treatment of anemia in nondialysis chronic kidney disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Use of blood transfusions
         </strong>
         – We avoid the use of blood transfusions whenever possible to minimize the risk of allosensitization and rejection. However, if a blood transfusion is necessary in a kidney transplant recipient, cytomegalovirus (CMV)-seronegative and/or filtered blood products are preferable to leukocyte-reduced products as CMV and other viruses may be transmitted in plasma [
         <a href="#rid54">
          54
         </a>
         ]. Irradiation of blood products is probably unnecessary [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1571623890">
         <span class="h2">
          Approach based on time from transplantation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Our approach to the management of anemia in kidney transplant recipients differs depending upon the time from transplant and the cause of anemia. (See
         <a class="local">
          'Diagnostic evaluation'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H1980574548">
         <span class="h3">
          Patients awaiting transplantation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Anemia in patients who are awaiting a kidney transplant should be managed with the same approach used to treat anemia in the general CKD or ESKD population. Whenever possible, the use of RBC transfusions should be avoided to minimize the risk of immunologic sensitization, which may delay or reduce the possibility of receiving a transplant [
         <a href="#rid56">
          56
         </a>
         ]. This is consistent with the 2012 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines for the treatment of anemia in patients eligible for solid organ transplantation [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1952.html" rel="external">
          "Treatment of anemia in nondialysis chronic kidney disease"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1926.html" rel="external">
          "Treatment of anemia in patients on dialysis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H834651757">
         <span class="h3">
          Patients perioperative and early posttransplantation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Our approach in patients who are in the perioperative and immediately posttransplant period is as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Perioperatively, we target Hb levels of &gt;10 g/dL as these levels appear safe and may reduce cardiovascular events in the early posttransplant period [
         <a href="#rid57">
          57
         </a>
         ]. The pretransplant use of ESAs and iron in patients with dialysis and nondialysis CKD should maintain Hb levels in the range of 10 to 11.5 g/dL, therefore minimizing the need for peritransplant RBC transfusions. We limit RBC transfusions to patients with an Hb &lt;7 g/dL or &lt;8 g/dL in those with preexisting cardiovascular disease (CVD). This is consistent with the 2016 Clinical Practice Guidelines of the American Association of Blood Banks [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients with an Hb &lt;10 g/dL and evidence of iron deficiency (ie, transferrin saturation [TSAT] ≤20 percent and serum ferritin level ≤200 ng/mL) at the time of transplantation, we administer 1 g of IV iron (typically as
         <a class="drug drug_general" data-topicid="9004" href="/z/d/drug information/9004.html" rel="external">
          iron sucrose
         </a>
         ) in anticipation of iron losses with phlebotomy during the early posttransplant period. This approach is based on our clinical experience and is not supported by high-quality evidence.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients who were previously receiving ESA therapy, we stop the ESA at the time of transplant because of hyporesponsiveness to ESAs in the early posttransplant period, the thrombotic and cardiovascular risks of these drugs, and the expectation that endogenous erythropoietin (EPO) production will occur posttransplant. We do not give ESAs to patients with delayed graft function, as use of ESA therapy in this population is controversial and responsiveness to ESAs may be poor.
        </p>
        <p>
        </p>
        <p>
         ESA therapy in the immediate posttransplant setting shortens the time to improved Hb [
         <a href="#rid59">
          59
         </a>
         ] but has not been shown to improve clinical outcomes [
         <a href="#rid60">
          60
         </a>
         ]. In a randomized trial of 104 patients that examined the efficacy of high-dose epoetin beta before transplant and during the first two weeks posttransplant, there was no difference in the frequency of delayed graft function between patients who received and did not receive epoetin [
         <a href="#rid61">
          61
         </a>
         ]. Similarly, a retrospective study found no difference in three-month Hb levels or delayed graft function between patients who received and did not receive EPO during the first six months posttransplant [
         <a href="#rid62">
          62
         </a>
         ].
        </p>
        <p>
         Two studies have examined the effect of high-dose EPO on delayed or slow graft function [
         <a href="#rid63">
          63,64
         </a>
         ]. In one study, 72 patients were randomly assigned to receive an intra-arterial injection of epoetin (40,000 units) or placebo at the time of reperfusion of the transplanted kidney. There was no difference between groups in the need for dialysis within the first week or in the percentage of patients with slow graft function (defined as ≤40 percent decrease in serum creatinine by postoperative day 3). The second trial randomly assigned 92 patients to IV epoetin (33,000 units) daily for three doses, beginning three to four hours before transplantation. Epoetin treatment had no effect on the incidence or duration of delayed graft function but did increase the risk of thrombotic events at one month and one year [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3139134264">
         <span class="h3">
          Patients later (&gt;3 months) posttransplantation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Anemia in the immediate posttransplant setting typically improves within two to three months with endogenous EPO production from the allograft. However, several factors, including immunosuppressive agents, other medications (such as ACE inhibitors and ARBs), graft dysfunction, and infections, may contribute to the persistence or new onset of anemia after the early posttransplant period. Such potentially correctable factors should be identified and treated as appropriate prior to the initiation of ESA therapy. In addition, the approach to the treatment of anemia in transplant recipients who are &gt;3 months posttransplant depends upon the functional status of the kidney allograft. (See
         <a class="local">
          'Diagnostic evaluation'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H1749158773">
         <span class="h4">
          Patients with stable graft function
         </span>
         <span class="headingEndMark">
          —
         </span>
         In kidney transplant patients with stable graft function (estimated glomerular filtration rate [eGFR] ≥45 mL/min/1.73 m
         <sup>
          2
         </sup>
         ), our approach is as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients with evidence of folate and/or vitamin B12 deficiency, we treat as appropriate to correct the deficiency, as discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7154.html" rel="external">
          "Treatment of vitamin B12 and folate deficiencies"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients with evidence of iron deficiency, we treat with IV iron. Dosing and administration of IV iron is presented elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/1943.html" rel="external">
          "Treatment of iron deficiency in patients with nondialysis chronic kidney disease (CKD)", section on 'Intravenous iron'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients who do not have a clearly identifiable cause of anemia and are taking an ACE inhibitor or ARB, we weigh the potential risks and benefits of continuing these medications. If the patient does not require the ACE inhibitor or ARB for management of another comorbidity (eg, heart failure), then it is reasonable to discontinue the ACE inhibitor or ARB and monitor for improvement of anemia. If the anemia improves, the ACE inhibitor or ARB can be reintroduced at a later time (eg, after one year), if indicated, with monitoring for worsening of the anemia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients who are receiving higher doses of an antimetabolite (eg, MMF 1000 mg twice daily or EC-MPS 720 mg twice daily) as part of their maintenance immunosuppression regimen, if anemia is severe and dose reduction is possible given the patient's immunologic risk of rejection, we reduce the dose of the antimetabolite by 50 percent. As an example, if the patient is on EC-MPS 720 mg twice daily, we decrease the dose to 360 mg twice daily. Similarly, if the patient is on MMF 1000 mg twice daily, we decrease the dose to 500 mg twice daily.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients who are receiving
         <a class="drug drug_general" data-topicid="8485" href="/z/d/drug information/8485.html" rel="external">
          ganciclovir
         </a>
         and/or TMP-SMX, we make sure that these agents are appropriately dosed for the level of kidney allograft function. We do not routinely dose reduce or discontinue these agents to treat anemia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If anemia persists in spite of treatment of the above potentially reversible causes, we initiate an ESA in patients with an Hb &lt;9 g/dL and target Hb levels of 10 to 11.5 g/dL, which are similar to those suggested for most patients with nondialysis and dialysis CKD. During routine management, patients may exceed 11 g/dL, and the dose of ESA should be temporarily stopped or reduced 25 percent monthly until the target is achieved. (See
         <a class="medical medical_review" href="/z/d/html/1952.html" rel="external">
          "Treatment of anemia in nondialysis chronic kidney disease", section on 'Target hemoglobin value'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1926.html" rel="external">
          "Treatment of anemia in patients on dialysis", section on 'Target Hb levels'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         The optimum target Hb level for transplant recipients with stable graft function is not known. Observational studies in kidney transplant recipients have suggested that mortality may be increased with Hb levels &gt;12.5 g/dL [
         <a href="#rid65">
          65,66
         </a>
         ].
        </p>
        <p>
         However, one study has suggested that graft survival may be better among patients treated to higher Hb values [
         <a href="#rid67">
          67
         </a>
         ]. This two-year, open-label trial (Correction of Anemia and Progression of Renal Insufficiency in Transplant Patients [CAPRIT]) of 125 kidney transplant recipients with an estimated creatinine clearance &lt;50 mL/min/1.73 m
         <sup>
          2
         </sup>
         randomly assigned patients to receive epoetin with a target of 13 to 15 g/dL (complete correction group) or 10.5 to 11.5 g/dL (partial correction group) [
         <a href="#rid67">
          67
         </a>
         ]. Compared with the partial correction group, the complete correction group had a smaller decrease in estimated creatinine clearance (5.9 versus 2.4 mL/min/1.73 m
         <sup>
          2
         </sup>
         ), lower rate of ESKD (21 versus 4.8 percent), and higher death-censored graft survival (80 versus 95 percent). The CAPRIT trial is limited by its short duration, open-label design, and small size [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p>
         These results are strikingly different from those observed in the much larger Correction of Hemoglobin and Outcomes in Renal Insufficiency (CHOIR) and Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) trials, which randomly assigned patients with nontransplant CKD [
         <a href="#rid69">
          69,70
         </a>
         ]. The CHOIR and TREAT trials found an increased risk of cardiovascular events and no delay in progressive kidney failure by targeting normalization of Hb with ESA therapy. The Cardiovascular Reduction Early Anemia Treatment Epoetin beta (CREATE) trial employed anemia management similar to CAPRIT and found that randomization to a higher Hb target significantly increased the likelihood of initiating chronic dialysis [
         <a href="#rid71">
          71
         </a>
         ]. We find it difficult to conceive of mechanisms by which somewhat higher Hb and/or more ESA could protect a transplant kidney but not native kidneys.
        </p>
        <p>
         Much larger trials comparing ESA treatment with placebo are needed to define the risks and benefits of anemia management in transplant recipients.
        </p>
        <p>
         The administration of
         <a class="drug drug_general" data-topicid="8662" href="/z/d/drug information/8662.html" rel="external">
          darbepoetin alfa
         </a>
         is also generally effective in kidney transplant recipients. In a retrospective, 12-week study of 36 patients, 81 percent achieved the target Hb level of &gt;12 g/dL (mean time to response of 4.4 weeks) [
         <a href="#rid72">
          72
         </a>
         ]. A longer duration of therapy was required in those with longstanding anemia and/or exposure to concurrent ACE inhibitor therapy.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="140715" href="/z/d/drug information/140715.html" rel="external">
          Daprodustat
         </a>
         , an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, has been approved for treatment of anemia in patients with ESKD on dialysis but is not approved for use in patients with nondialysis CKD. Further study of the safety of this class of agents in kidney transplant recipients is needed before its use can be considered.
        </p>
        <p class="headingAnchor" id="H1812905011">
         <span class="h4">
          Patients with a failing graft
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with failing transplants in stage 4 to 5 CKD frequently become anemic, and ESA therapy may be required to alleviate symptoms and reduce the risk of transfusions. The management of anemia in this patient population is similar to that in the general CKD or ESKD population, except that higher doses of ESAs may be required due to chronic inflammation. As discussed above for patients with stable graft function, we address any potential reversible causes (eg, nutritional deficiency, iron deficiency, immunosuppression, other medications) (see
         <a class="local">
          'Patients with stable graft function'
         </a>
         above). We generally initiate ESA therapy when the Hg is 9 to 10 g/dL and the iron stores appear adequate. We assess the risks from ESA therapy, which are higher in those with CVD, prior thrombotic events, stroke, or cancer. In patients with higher risks from ESA therapy, we generally avoid ESAs until anemia is more severe (ie, Hb &lt;9 g/dL). (See
         <a class="medical medical_review" href="/z/d/html/1952.html" rel="external">
          "Treatment of anemia in nondialysis chronic kidney disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1926.html" rel="external">
          "Treatment of anemia in patients on dialysis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1935.html" rel="external">
          "Hyporesponse to erythropoiesis-stimulating agents (ESAs) in chronic kidney disease", section on 'Infection or inflammation'
         </a>
         .)
        </p>
        <p>
         Kidney transplant recipients restarting dialysis have lower Hb levels when compared with patients with nontransplant CKD (Hb levels of 8.9 versus 10.2 g/dL, respectively), which correlate with increased hospitalizations and higher mortality [
         <a href="#rid5">
          5
         </a>
         ]. Use of ESAs such as epoetin may reduce the frequency and severity of anemia in patients with failing transplants but have not been shown to reduce mortality [
         <a href="#rid73">
          73
         </a>
         ].
        </p>
        <p>
         Patients who have returned to dialysis and are resistant to ESAs may benefit from allograft nephrectomy. (See
         <a class="local">
          'Later (&gt;3 months) posttransplantation'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H1462388680">
         <span class="h2">
          Special populations
         </span>
        </p>
        <p class="headingAnchor" id="H3715914618">
         <span class="h3">
          Patients with parvovirus B19 infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Anemia caused by parvovirus B19 infection has been corrected by treatment with IV
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         (IVIG) and by lowering immunosuppression to facilitate viral clearance [
         <a href="#rid51">
          51
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8330.html" rel="external">
          "Treatment and prevention of parvovirus B19 infection"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1945882365">
         <span class="h3">
          Patients with thrombotic microangiopathy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The treatment of thrombotic microangiopathy in kidney transplant recipients is discussed in more detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7350.html" rel="external">
          "Thrombotic microangiopathy after kidney transplantation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2978102797">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Conflicting results have been found relating to the prognosis of kidney transplant recipients with anemia [
         <a href="#rid74">
          74-76
         </a>
         ]. To better define this relationship, the correlation between anemia (defined as &lt;12 g/dL in females and &lt;13 g/dL in males) and patient and allograft survival was evaluated in a prospective cohort study of 938 kidney transplant recipients [
         <a href="#rid66">
          66
         </a>
         ]. At four years, multivariate analysis revealed that anemia was associated with an increased risk of mortality (hazard ratio [HR] 1.69, 95% CI 1.15-2.5) and allograft failure (HR 2.56, 95% CI 1.48-4.1). Similar results were observed when anemia was defined as &lt;11 g/dL.
        </p>
        <p>
         However, an analysis of 825 kidney transplant recipients over 8.2 years found no relationship of anemia to mortality in multivariate analyses [
         <a href="#rid74">
          74
         </a>
         ].
        </p>
        <p>
         In the Assessment of Lescol in Renal Transplantation (ALERT) study of 2102 kidney transplant recipients, in which 29 percent of females and 30 percent of males were anemic, hemoglobin (Hb) levels were not associated with any effect on cardiovascular morbidity and mortality (HR 0.97, 95% CI 0.90-1.05 per g/dL) or all-cause death (HR 0.96, 95% CI 0.90-1.03 per g/dL) after extensive multivariate adjustments for clinical and demographic factors [
         <a href="#rid77">
          77
         </a>
         ]. Hb levels, however, were negatively associated with graft loss (HR 0.86, 95% CI 0.80-0.92 per g/dL).
        </p>
        <p>
         Left ventricular hypertrophy (LVH), an important risk factor for cardiovascular mortality among patients with CKD, may be in part a consequence of untreated anemia. Since cardiovascular disease (CVD) is the leading cause of death in diabetic kidney transplant recipients, the adverse effects of anemia may be more evident in diabetic kidney transplant recipients in the United States, when compared with other nationalities, as the United States transplant population has a relatively higher cardiovascular risk profile, with a higher percentage of patients with diabetes. Unfortunately, existing trials have not demonstrated that aggressive treatment of anemia regresses or retards progression of LVH, and any benefit of ESA therapy may be outweighed by the risks of these drugs [
         <a href="#rid69">
          69,70,78
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1925.html" rel="external">
          "Cardiovascular and renal effects of anemia in chronic kidney disease", section on 'Left ventricular hypertrophy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1926.html" rel="external">
          "Treatment of anemia in patients on dialysis", section on 'Adverse effects of ESAs'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1181392762">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/110754.html" rel="external">
          "Society guideline links: Kidney transplantation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Overview
         </strong>
         – Anemia, usually defined as hemoglobin (Hb) &lt;12 g/dL in females and &lt;13 g/dL in males, is a common finding before and after kidney transplantation. It is most often related to iron deficiency, graft rejection or dysfunction, erythropoietin (EPO) deficiency, viral infection, immunosuppression, and infection prophylaxis medications. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology
         </strong>
         – While anemia is present in almost 90 percent of patients in the first month posttransplant, the prevalence falls to 34 to 45 percent among patients more than one year posttransplant depending upon the definition of anemia used, time period posttransplant, and immunosuppressive regimen. Anemia early posttransplantation generally corrects without intervention. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathogenesis
         </strong>
         – The pathogenesis of anemia posttransplant varies by time from transplant and by patient characteristics. Anemia immediately posttransplant is almost universally due to lower-than-normal Hb targets in the chronic kidney disease (CKD) and end-stage kidney disease (ESKD) populations, surgical blood loss, frequent phlebotomy, and iron deficiency. Persistence or new onset of anemia after the early posttransplant period may be caused by several factors including immunosuppressive agents, other medications (such as angiotensin-converting enzyme [ACE] inhibitors and angiotensin receptor blockers [ARBs]), graft dysfunction, and infections. (See
         <a class="local">
          'Pathogenesis and risk factors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Surveillance
         </strong>
         – Kidney transplant recipients should be regularly screened for anemia after transplantation with a complete blood count (CBC). At most transplant centers, a CBC is obtained weekly for the first three months, then every two to four weeks out to one year and then monthly to every three months thereafter. (See
         <a class="local">
          'Surveillance'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnostic evaluation
         </strong>
         – Kidney transplant recipients who are found to have persistent (ie, Hb levels that fail to normalize at three months posttransplant) or new-onset anemia should undergo a diagnostic evaluation to determine the cause of anemia. Such an evaluation should include an assessment for causes of anemia shared with nontransplant patients, as well as for more specific causes that may be unique to kidney transplant recipients. (See
         <a class="local">
          'Diagnostic evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment
         </strong>
         – The general principles of anemia management in patients with CKD or ESKD also apply to the treatment of anemia in kidney transplant recipients. These include treatment of the underlying cause of anemia (if identified), treatment of iron deficiency (if present), and the use of erythropoiesis-stimulating agents (ESAs) to reduce the need for red blood cell (RBC) transfusions. As in nontransplant patients with CKD or ESKD, the selection of individual therapy depends upon the severity of anemia and the presence of iron deficiency. Anemic patients who are iron deficient should be treated with iron before the administration of ESAs. (See
         <a class="local">
          'Treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Foley RN, Parfrey PS, Morgan J, et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 2000; 58:1325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vanrenterghem Y, Ponticelli C, Morales JM, et al. Prevalence and management of anemia in renal transplant recipients: a European survey. Am J Transplant 2003; 3:835.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mix TC, Kazmi W, Khan S, et al. Anemia: a continuing problem following kidney transplantation. Am J Transplant 2003; 3:1426.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yorgin PD, Scandling JD, Belson A, et al. Late post-transplant anemia in adult renal transplant recipients. An under-recognized problem? Am J Transplant 2002; 2:429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arias M, Escallada R, de Francisco AL, et al. Return to dialysis after renal transplantation. Which would be the best way? Kidney Int Suppl 2002; :85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gill JS, Abichandani R, Khan S, et al. Opportunities to improve the care of patients with kidney transplant failure. Kidney Int 2002; 61:2193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lorenz M, Kletzmayr J, Perschl A, et al. Anemia and iron deficiencies among long-term renal transplant recipients. J Am Soc Nephrol 2002; 13:794.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zheng S, Coyne DW, Joist H, et al. Iron deficiency anemia and iron losses after renal transplantation. Transpl Int 2009; 22:434.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Winkelmayer WC, Chandraker A. Pottransplantation anemia: management and rationale. Clin J Am Soc Nephrol 2008; 3 Suppl 2:S49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vanrenterghem Y. Anemia after kidney transplantation. Transplantation 2009; 87:1265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones H, Talwar M, Nogueira JM, et al. Anemia after kidney transplantation; its prevalence, risk factors, and independent association with graft and patient survival: a time-varying analysis. Transplantation 2012; 93:923.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Teruel JL, Lamas S, Vila T, et al. Serum ferritin levels after renal transplantation: a prospective study. Nephron 1989; 51:462.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shibagaki Y, Shetty A. Anaemia is common after kidney transplantation, especially among African Americans. Nephrol Dial Transplant 2004; 19:2368.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lim AKH, Kansal A, Kanellis J. Factors associated with anaemia in kidney transplant recipients in the first year after transplantation: a cross-sectional study. BMC Nephrol 2018; 19:252.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miles AM, Markell MS, Daskalakis P, et al. Anemia following renal transplantation: erythropoietin response and iron deficiency. Clin Transplant 1997; 11:313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krischock LA, van Stralen KJ, Verrina E, et al. Anemia in children following renal transplantation-results from the ESPN/ERA-EDTA Registry. Pediatr Nephrol 2016; 31:325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Winkelmayer WC, Kewalramani R, Rutstein M, et al. Pharmacoepidemiology of anemia in kidney transplant recipients. J Am Soc Nephrol 2004; 15:1347.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shah N, Al-Khoury S, Afzali B, et al. Posttransplantation anemia in adult renal allograft recipients: prevalence and predictors. Transplantation 2006; 81:1112.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beshara S, Birgegård G, Goch J, et al. Assessment of erythropoiesis following renal transplantation. Eur J Haematol 1997; 58:167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Besarab A, Caro J, Jarrell BE, et al. Dynamics of erythropoiesis following renal transplantation. Kidney Int 1987; 32:526.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Serre AF, Souweine B, Evreux O, et al. Reticulocyte response to endogenous erythropoietin after renal transplantation. Clin Transplant 1994; 8:353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wikström B, Goch J, Danielson BG, et al. Serum erythropoietin in renal transplant patients. Transplant Proc 1989; 21:2043.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim HC, Park SB, Han SY, Whang EA. Anemia following renal transplantation. Transplant Proc 2003; 35:302.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Douwes RM, Gomes-Neto AW, Schutten JC, et al. Proton-Pump Inhibitors and Hypomagnesaemia in Kidney Transplant Recipients. J Clin Med 2019; 8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nicolas G, Chauvet C, Viatte L, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 2002; 110:1037.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malyszko J, Malyszko JS, Mysliwiec M. A possible role of hepcidin in the pathogenesis of anemia among kidney allograft recipients. Transplant Proc 2009; 41:3056.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Oers MH, Van der Heyden AA, Aarden LA. Interleukin 6 (IL-6) in serum and urine of renal transplant recipients. Clin Exp Immunol 1988; 71:314.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004; 113:1271.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moore LW, Smith SO, Winsett RP, et al. Factors affecting erythropoietin production and correction of anemia in kidney transplant recipients. Clin Transplant 1994; 8:358.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moulin B, Ollier J, George F, et al. Serum erythropoietin and reticulocyte maturity index after renal transplantation: a prospective longitudinal study. Nephron 1995; 69:259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsuchimoto A, Masutani K, Haruyama N, et al. Renal interstitial fibrosis in 0-hour biopsy as a predictor of post-transplant anemia. Am J Nephrol 2013; 38:267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Imoagene-Oyedeji AE, Rosas SE, Doyle AM, et al. Posttransplantation anemia at 12 months in kidney recipients treated with mycophenolate mofetil: risk factors and implications for mortality. J Am Soc Nephrol 2006; 17:3240.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gonwa T, Mendez R, Yang HC, et al. Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months. Transplantation 2003; 75:1213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oberbauer R, Kreis H, Johnson RW, et al. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study. Transplantation 2003; 76:364.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Augustine JJ, Knauss TC, Schulak JA, et al. Comparative effects of sirolimus and mycophenolate mofetil on erythropoiesis in kidney transplant patients. Am J Transplant 2004; 4:2001.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Turkowski-Duhem A, Kamar N, Cointault O, et al. Predictive factors of anemia within the first year post renal transplant. Transplantation 2005; 80:903.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fishbane S, Cohen DJ, Coyne DW, et al. Posttransplant anemia: the role of sirolimus. Kidney Int 2009; 76:376.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stigant CE, Cohen J, Vivera M, Zaltzman JS. ACE inhibitors and angiotensin II antagonists in renal transplantation: an analysis of safety and efficacy. Am J Kidney Dis 2000; 35:58.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hedvat J, Poladi N, Salerno DM, et al. An evaluation of PJP prophylaxis and anemia among renal transplant recipients. Transpl Infect Dis 2021; 23:e13543.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           López-Gómez JM, Pérez-Flores I, Jofré R, et al. Presence of a failed kidney transplant in patients who are on hemodialysis is associated with chronic inflammatory state and erythropoietin resistance. J Am Soc Nephrol 2004; 15:2494.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Egbuna O, Zand MS, Arbini A, et al. A cluster of parvovirus B19 infections in renal transplant recipients: a prospective case series and review of the literature. Am J Transplant 2006; 6:225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahmud SN, Aziz R, Ahmed E, et al. Anemia characteristics after renal transplantation. Transplant Proc 2002; 34:2428.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pomper GJ, Joseph RA, Hartmann EL, et al. Massive immune hemolysis caused by anti-D after dual kidney transplantation. Am J Transplant 2005; 5:2586.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramsey G. Red cell antibodies arising from solid organ transplants. Transfusion 1991; 31:76.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Petz LD. Immune hemolysis associated with transplantation. Semin Hematol 2005; 42:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramsey G, Israel L, Lindsay GD, et al. Anti-Rho(D) in two Rh-positive patients receiving kidney grafts from an Rh-immunized donor. Transplantation 1986; 41:67.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ainsworth CD, Crowther MA, Treleaven D, et al. Severe hemolytic anemia post-renal transplantation produced by donor anti-D passenger lymphocytes: case report and literature review. Transfus Med Rev 2009; 23:155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marton A, Pendergrast JM, Kshavjee S, et al. Passenger Lymphocyte Syndrome Following Solid Organ Transplantation: Graft Source, Incidence, Specificity, Duration, and Severity Of Hemolysis. Blood 2013; 122:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahrens N, Hutchinson JA. Passenger Leucocyte Syndrome. Transplantation 2016; 100:1787.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chapter 1: Diagnosis and evaluation of anemia in CKD. Kidney Int Suppl (2011) 2012; 2:288.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meeus G, Messiaen T, Verhoef G, Vanrenterghem Y. New-onset anaemia following kidney transplantation. Nephrol Dial Transplant 2000; 15:2059.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mudge DW, Tan KS, Miles R, et al. A randomized controlled trial of intravenous or oral iron for posttransplant anemia in kidney transplantation. Transplantation 2012; 93:822.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vinke JSJ, Francke MI, Eisenga MF, et al. Iron deficiency after kidney transplantation. Nephrol Dial Transplant 2021; 36:1976.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nichols WG, Price TH, Gooley T, et al. Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products. Blood 2003; 101:4195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Triulzi DJ. Specialized transfusion support for solid organ transplantation. Curr Opin Hematol 2002; 9:527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Obrador GT, Macdougall IC. Effect of red cell transfusions on future kidney transplantation. Clin J Am Soc Nephrol 2013; 8:852.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Djamali A, Becker YT, Simmons WD, et al. Increasing hematocrit reduces early posttransplant cardiovascular risk in diabetic transplant recipients. Transplantation 2003; 76:816.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carson JL, Guyatt G, Heddle NM, et al. Clinical Practice Guidelines From the AABB: Red Blood Cell Transfusion Thresholds and Storage. JAMA 2016; 316:2025.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Loo A, Vanholder R, Bernaert P, et al. Recombinant human erythropoietin corrects anaemia during the first weeks after renal transplantation: a randomized prospective study. Nephrol Dial Transplant 1996; 11:1815.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elliott S, Tomita D, Endre Z. Erythropoiesis stimulating agents and reno-protection: a meta-analysis. BMC Nephrol 2017; 18:14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martinez F, Kamar N, Pallet N, et al. High dose epoetin beta in the first weeks following renal transplantation and delayed graft function: Results of the Neo-PDGF Study. Am J Transplant 2010; 10:1695.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mohiuddin MK, El-Asir L, Gupta A, et al. Perioperative erythropoietin efficacy in renal transplantation. Transplant Proc 2007; 39:132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aydin Z, Mallat MJ, Schaapherder AF, et al. Randomized trial of short-course high-dose erythropoietin in donation after cardiac death kidney transplant recipients. Am J Transplant 2012; 12:1793.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sureshkumar KK, Hussain SM, Ko TY, et al. Effect of high-dose erythropoietin on graft function after kidney transplantation: a randomized, double-blind clinical trial. Clin J Am Soc Nephrol 2012; 7:1498.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heinze G, Kainz A, Hörl WH, Oberbauer R. Mortality in renal transplant recipients given erythropoietins to increase haemoglobin concentration: cohort study. BMJ 2009; 339:b4018.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Molnar MZ, Czira M, Ambrus C, et al. Anemia is associated with mortality in kidney-transplanted patients--a prospective cohort study. Am J Transplant 2007; 7:818.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choukroun G, Kamar N, Dussol B, et al. Correction of postkidney transplant anemia reduces progression of allograft nephropathy. J Am Soc Nephrol 2012; 23:360.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mehrotra A. ESAs in transplant anemia: one size does not "fit all". J Am Soc Nephrol 2012; 23:192.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355:2085.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361:2019.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drüeke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355:2071.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McDevitt LM, Smith LD, Somerville KT, et al. A retrospective assessment of pre-treatment variables on the response to darbepoetin alfa after renal transplantation. Am J Transplant 2005; 5:1948.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arias M, Hernández D, Guirado L, et al. Clinical profile and post-transplant anaemia in renal transplant recipients restarting dialysis after a failed graft: changing trends between 2001 and 2009. Clin Kidney J 2013; 6:156.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Winkelmayer WC, Chandraker A, Alan Brookhart M, et al. A prospective study of anaemia and long-term outcomes in kidney transplant recipients. Nephrol Dial Transplant 2006; 21:3559.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heinze G, Mitterbauer C, Regele H, et al. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol 2006; 17:889.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kamar N, Rostaing L. Negative impact of one-year anemia on long-term patient and graft survival in kidney transplant patients receiving calcineurin inhibitors and mycophenolate mofetil. Transplantation 2008; 85:1120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schjelderup P, Dahle DO, Holdaas H, et al. Anemia is a predictor of graft loss but not cardiovascular events and all-cause mortality in renal transplant recipients: follow-up data from the ALERT study. Clin Transplant 2013; 27:E636.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parfrey PS, Foley RN, Wittreich BH, et al. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 2005; 16:2180.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 7330 Version 31.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10972697" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12814475" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Prevalence and management of anemia in renal transplant recipients: a European survey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14525605" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Anemia: a continuing problem following kidney transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12123208" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Late post-transplant anemia in adult renal transplant recipients. An under-recognized problem?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11982819" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Return to dialysis after renal transplantation. Which would be the best way?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12028460" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Opportunities to improve the care of patients with kidney transplant failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11856787" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Anemia and iron deficiencies among long-term renal transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19076330" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Iron deficiency anemia and iron losses after renal transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18309003" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Pottransplantation anemia: management and rationale.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19424022" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Anemia after kidney transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22377790" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Anemia after kidney transplantation; its prevalence, risk factors, and independent association with graft and patient survival: a time-varying analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2662035" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Serum ferritin levels after renal transplantation: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15213318" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Anaemia is common after kidney transplantation, especially among African Americans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30290796" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Factors associated with anaemia in kidney transplant recipients in the first year after transplantation: a cross-sectional study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9267720" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Anemia following renal transplantation: erythropoietin response and iron deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26385862" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Anemia in children following renal transplantation-results from the ESPN/ERA-EDTA Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15100376" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Pharmacoepidemiology of anemia in kidney transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16641595" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Posttransplantation anemia in adult renal allograft recipients: prevalence and predictors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9150710" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Assessment of erythropoiesis following renal transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3323595" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Dynamics of erythropoiesis following renal transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7949538" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Reticulocyte response to endogenous erythropoietin after renal transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2652669" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Serum erythropoietin in renal transplant patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12591412" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Anemia following renal transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31817776" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Proton-Pump Inhibitors and Hypomagnesaemia in Kidney Transplant Recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12370282" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19857675" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : A possible role of hepcidin in the pathogenesis of anemia among kidney allograft recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3280187" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Interleukin 6 (IL-6) in serum and urine of renal transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15124018" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7949539" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Factors affecting erythropoietin production and correction of anemia in kidney transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7753259" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Serum erythropoietin and reticulocyte maturity index after renal transplantation: a prospective longitudinal study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24052081" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Renal interstitial fibrosis in 0-hour biopsy as a predictor of post-transplant anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17035616" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Posttransplantation anemia at 12 months in kidney recipients treated with mycophenolate mofetil: risk factors and implications for mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12717205" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12883194" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15575902" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Comparative effects of sirolimus and mycophenolate mofetil on erythropoiesis in kidney transplant patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16249737" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Predictive factors of anemia within the first year post renal transplant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19553912" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Posttransplant anemia: the role of sirolimus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10620545" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : ACE inhibitors and angiotensin II antagonists in renal transplantation: an analysis of safety and efficacy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33280205" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : An evaluation of PJP prophylaxis and anemia among renal transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15340000" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Presence of a failed kidney transplant in patients who are on hemodialysis is associated with chronic inflammatory state and erythropoietin resistance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16433780" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : A cluster of parvovirus B19 infections in renal transplant recipients: a prospective case series and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12270467" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Anemia characteristics after renal transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16162213" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Massive immune hemolysis caused by anti-D after dual kidney transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1986468" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Red cell antibodies arising from solid organ transplants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16041664" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Immune hemolysis associated with transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3001981" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Anti-Rho(D) in two Rh-positive patients receiving kidney grafts from an Rh-immunized donor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19304116" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Severe hemolytic anemia post-renal transplantation produced by donor anti-D passenger lymphocytes: case report and literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Passenger Lymphocyte Syndrome Following Solid Organ Transplantation: Graft Source, Incidence, Specificity, Duration, and Severity Of Hemolysis
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27542067" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Passenger Leucocyte Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25018948" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Chapter 1: Diagnosis and evaluation of anemia in CKD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11096157" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : New-onset anaemia following kidney transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22290270" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : A randomized controlled trial of intravenous or oral iron for posttransplant anemia in kidney transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32910168" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Iron deficiency after kidney transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12531791" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12394177" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Specialized transfusion support for solid organ transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23085723" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Effect of red cell transfusions on future kidney transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14501860" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Increasing hematocrit reduces early posttransplant cardiovascular risk in diabetic transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27732721" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Clinical Practice Guidelines From the AABB: Red Blood Cell Transfusion Thresholds and Storage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8918628" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Recombinant human erythropoietin corrects anaemia during the first weeks after renal transplantation: a randomized prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28077085" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Erythropoiesis stimulating agents and reno-protection: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20642691" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : High dose epoetin beta in the first weeks following renal transplantation and delayed graft function: Results of the Neo-PDGF Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17275489" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Perioperative erythropoietin efficacy in renal transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22429395" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Randomized trial of short-course high-dose erythropoietin in donation after cardiac death kidney transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22745272" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Effect of high-dose erythropoietin on graft function after kidney transplantation: a randomized, double-blind clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19854839" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Mortality in renal transplant recipients given erythropoietins to increase haemoglobin concentration: cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17391125" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Anemia is associated with mortality in kidney-transplanted patients--a prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22193388" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Correction of postkidney transplant anemia reduces progression of allograft nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22241895" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : ESAs in transplant anemia: one size does not "fit all".
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17108343" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Correction of anemia with epoetin alfa in chronic kidney disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19880844" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17108342" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Normalization of hemoglobin level in patients with chronic kidney disease and anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15996244" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : A retrospective assessment of pre-treatment variables on the response to darbepoetin alfa after renal transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26019844" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Clinical profile and post-transplant anaemia in renal transplant recipients restarting dialysis after a failed graft: changing trends between 2001 and 2009.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17040993" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : A prospective study of anaemia and long-term outcomes in kidney transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16481415" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18431231" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Negative impact of one-year anemia on long-term patient and graft survival in kidney transplant patients receiving calcineurin inhibitors and mycophenolate mofetil.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23991916" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Anemia is a predictor of graft loss but not cardiovascular events and all-cause mortality in renal transplant recipients: follow-up data from the ALERT study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15901766" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
